Innocoll AG (INNL) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update
November 11, 2015 8:01 AM ESTATHLONE, Ireland, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and nine months ended September 30, 2015.
The third quarter was another one of execution on our clinical plans for XaraColl and Cogenzia as well as positioning these products for successful commercialization, said Tony Zook, Chief Executive Officer of Innocoll. A total of four Phase 3 trials, two each for XaraColl... More
